ArticleBMC cancer2025
Mechanistic role of FN1 in LAIR-1 mediated downregulation of ovarian cancer cell proliferation.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring the potential targets and molecular mechanisms of cordycepin against gastric cancer based on bioinformatics analysis and network pharmacology.Journal of clinical biochemistry and nutrition · 2026Article
- Development and validation of an m6A and autophagy related lncRNAs signature for predicting survival and modulating the immune microenvironment in esophageal squamous cell carcinoma.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveRNA-seq was used to explore the potential mechanism underlying human leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) inhibition of the proliferation and migration of ovarian cancer cells.
methodA LAIR-1-overexpression cell model was established using a LAIR-1-lentivirus. After confirming and identifying the LAIR-1 expression cell clones by flow cytometry and RT-qPCR, the proliferation and migration of the cells were examined by CCK8 and scratch assays, and the differentially expressed genes (DEGs) were searched by RNA-seq and analyzed by GO and KEGG enrichment. String was used for protein interaction network analysis, and Cytoscape was used to identify key proteins.
resultsLAIR-1 inhibited the proliferation and migration of ovarian cancer cells. LAIR-1 expression caused the upregulation of 83 genes and the downregulation of 80 genes. Among the DEGs, fibronectin 1 (FN1) was a key protein affecting the downstream FAK-MEK-ERK axis. KEGG enrichment analysis identified the MAPK pathway as the most obvious enrichment pathway, followed by PI3K-AKT pathway.
conclusionLAIR-1 downregulates FN1 to inhibit the FAK-MEK-ERK axis, as well as the proliferation and migration of ovarian cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.